Rinatabart sesutecan
Rinatabart sesutecan is a next-generation folate-receptor ADC with a topoisomerase payload that responds in both ovarian and endometrial cancer regardless of receptor level.
Genmab (via ProfoundBio, 2024). RAINFOL-01: ORR 55.6% in ovarian cancer at 120 mg/m² and 50% in heavily pretreated endometrial cancer at 100 mg/m², the latter earning Breakthrough Therapy designation. Phase 3 RAINFOL-02 versus chemotherapy in platinum-resistant ovarian cancer is enrolling. Neutropenia and anaemia are dose-limiting; ocular toxicity is minimal compared with mirvetuximab.
1.Binds folate receptor alpha on the tumour cell
Compare all products across the US, EU, UK, Japan, China and Australia →
- 2025DesignationUS
Breakthrough Therapy designation, advanced endometrial cancer after PD-(L)1 and platinum source
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Latest papers
topQuery for this drug: (TITLE:"Rinatabart sesutecan" OR ABSTRACT:"Rinatabart sesutecan" OR TITLE:"Rina-S" OR ABSTRACT:"Rina-S" OR TITLE:"PRO1184" OR ABSTRACT:"PRO1184") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Rinatabart sesutecan, not a curated reading list.